Skip to main navigation Skip to search Skip to main content

MiR-215, an activator of the CTNNBIP1/ß-catenin pathway, is a marker of poor prognosis in human glioma

  • Yong Qing Tong
  • , Bei Liu
  • , Hong Yun Zheng
  • , Jian Gu
  • , Hang Liu
  • , Feng Li
  • , Bi Hua Tan
  • , Melanie Hartman
  • , Chunhua Song
  • , Yan Li

Research output: Contribution to journalArticlepeer-review

Abstract

MicroRNA-215 (miR-215) promotes tumor growth in various human malignancies. However, its role has not yet been determined in human glioma. Here, we found that levels of miR-215 were higher in glioma tissues than in corresponding non-neoplastic brain tissue. High miR-215 expression was correlated with higher World Health Organization (WHO) grades and shorter overall survival. Multivariate and univariate analysis indicated that miR-215 expression was an independent prognostic factor. We also found that TGF-beta1, phosphorylated beta-catenin, alpha-SMA, and fibronectin were increased in glioma tissues. Additionally, CTNNBIP1, a direct target of miR-215, was decreased in glioma compared to adjacent normal tissue. These data indicate that miR-215 activates Wnt/ß-catenin signaling by increasing ß-catenin phosphorylation, a-SMA expression, and fibronectin expression. It promotes TGF-ß1- induced oncogenesis by suppressing CTNNBIP1 in glioma. In summary, miR-215 is overexpressed in human glioma, is involved in TGF-ß1-induced oncogenesis, and can be used as a marker of poor prognosis in glioma patients.

Original languageEnglish (US)
Pages (from-to)25024-25033
Number of pages10
JournalOncotarget
Volume6
Issue number28
DOIs
StatePublished - 2015

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint

Dive into the research topics of 'MiR-215, an activator of the CTNNBIP1/ß-catenin pathway, is a marker of poor prognosis in human glioma'. Together they form a unique fingerprint.

Cite this